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Some of the pyrimidine and fused heterocyclic pyrimidine
derivatives have provided to be active antiviral, antitumor,
analgesic and antimicrobial (Amr et al., 2006; Mohamed65148750.
om (A.G.E. Amr).
ter the course of this work.
y. Production and hosting by
Saud University.
lsevieret al., 2010; Amr et al., 2009; Said et al., 2009; Mostafa
et al., 2008; Abd El-Hafez et al., 2009; Mohamed et al.,
2008; El-Gaby et al., 1999; Sayed and Ali, 2008; Mc Guigan
and Balzarini, 2006). In addition, pyrimidothiazine, thiazolo-
pyrimidine and oxazolidinione derivatives are antimicrobial
agents (Tozkoparan et al., 1999; Leach et al., 2007). Recently,
we have found that certain substituted pyrimidine and their
heterocyclic derivatives show antimicrobial, anti-inﬂammatory
(Amr et al., 2006; Amr and Abdalla, 2006; Amr et al., 2005)
and antitumor activities (Abo-Ghalia et al., 2004; Hammam
et al., 2003). On the other hand, thioxopyrimidine and thiazol-
opyrimidine derivatives have promising biological and anti-
cancer activities (Amr and Abdulla, 2002; Sayed et al., 2007;
Hafez et al., 2008; El-Gazzar et al., 2009; Hebat-Allah et al.,
2010). In view of these observations and in continuation of
our previous work in heterocyclic chemistry, we synthesized
some new pyrimidine and thiazolopyrimidine derivatives and
tested their antimicrobial activities.
510 U.W. Hawas et al.2. Results and discussion
A reaction of 3-methylcyclohexanone 1 with aromatic alde-
hydes, namely, 3,4-dimethoxy-, 3,4,5-trimethoxy-, p-chloro-,
p-ﬂouro-, or p-N,N-dimethylaminobenzaldehyde in ethanolic
potassium hydroxide gave the corresponding bis-arylmethyl-
ene derivatives 2a–e, respectively (Amr et al., 2006; Hammam
et al., 2003). Thioxopyrimidine derivatives 5a–d were obtained
from the reaction of the arylmethylene derivatives 2a–d with
thiourea in reﬂuxing ethanolic potassium hydroxide. Conden-
sation of compound 2a,b with hydrazine hydrate in glacial ace-
tic acid or with phenyl hydrazine in absolute ethanol in the
presence of triethylamine as a catalyst afforded the corre-
sponding pyrazole derivatives 3a,b and 4a,b, respectively
(Scheme 1).
Thioxopyrimidines 5a–d were condensed with chloroacetic
acid in a mixture of acetic acid/acetic anhydride in the presence
of anhydrous sodium acetate to yield the corresponding(1)
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Scheme 1 Synthetic routhiazolopyrimidines 6a–d, which were condensed with aromatic
aldehydes, namely, 3-bromo- or p-chloro- or 3,4,5-trimethoxy-
or 3-bromobenzaldehyde in the presence of anhydrous sodium
acetate and glacial acetic acid/acetic anhydride to yield the
target arylmethylene thiazolopyrimidine derivatives 7a–d,
respectively. However, the latter compounds were also pre-
pared directly from 5a–d by the action of chloroacetic acid,
aromatic aldehydes, namely, 3-bromo- or p-chloro- or 3,4,
5-trimethoxy- or 3-bromobenzaldehyde and anhydrous so-
dium acetate in the presence of an acetic acid/acetic anhydride
(Scheme 2).
3. Antimicrobial activity
Preliminary biological activity screening of the synthesized
compounds has been performed against microorganisms repre-
senting Gram-positive bacteria (Bacillus subtilis, Bacillus aur-
eus and Staphylococcus aureus), Gram-negative bacteria(2a-e)
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Scheme 2 Synthetic routes of compounds 6a–d and 7a–d.
Synthesis of some thiopyrimidine and thiazolopyrimidines 511(Escherichia coli), yeast (Candida albicans) and fungi (Aspergil-
lus niger), using the bioassay technique of antibiotics
(Abou-Zeid and Shehata, 1969) speciﬁed in US pharmacopeia
at 50 lg/ml. The most active compounds are: 3b, 4b, 5c, 6a, 7a
and 7d (Bacillus subtilis), 2e, 3a, 4a, 5b, 6c and 7b (Bacillus aur-
eus), 2b, 2e, 4b, 5d, 6d and 7c (Staphylococcus aureus), 2d, 3b,
6b and 7b (Escherichia coli), 2c, 3a, 6a, 7a and 7c (Candida albi-
cans), 2c, 4a, 5a, 5d, 6c and 7b (Aspergillus niger). Ampicillin
and chloramphenicol were used as standards. The results ob-
tained are summarized in Table 1.
4. Conclusion
From the obtained results, we can conclude that thiazolopyr-
imidine and substituted thiazolopyrimidine moieties fused to
3-methycyclohexane ring are essential for antimicrobial activi-
ties. Additionally, the difference in activity between the com-
pounds which is due to the presence of substituents in the
phenyl group of the molecule.
5. Experimental section
Melting points were determined on open glass capillaries using
an Electrothermal IA 9000 digital melting point apparatus
and are uncorrected. Elemental analyses were performed on
the Elementar, Vario EL, Micro-analytical Unit, National
Research Centre, Cairo, Egypt and were found within ±0.4%
of the theoretical values. Infrared spectra were recorded on the
Carlzeise Spectrophotometermodel ‘‘UR 10’’ spectrophotometer
using the KBr disc technique. 1HNMR spectra were recorded onthe Varian Gemini 270 MHz spectrometer (DMSO-d6) and the
chemical shifts are given ind (ppm)whichusedTMSasan internal
standard. The mass spectra were measured using a Finnigan SSQ
7000mass spectrometer. Follow-up of the reactions and checking
of the purity of the compounds were made by TLC on silica
gel-precoated aluminum sheets (Type 60F254,Merck,Darmstadt,
Germany). Compounds 2,6-bis-(3,4-dimethoxy-benzylidene)-3-
methylcyclohexanone 2a and 2,6-bis-(p-chlorobenzylidene)-3-
methylcyclohexanone 2c were reported before in the previous
literatures (Vorlander, 1925; Nerdel and Kreseze, 1955).
5.1. Synthesis of 2,6-bisarylmethylene-3-methylcyclohexanones
(2a–e)
5.1.1. Method A
A mixture of 3-methylcyclohexanone 1 (1.12 g, 10 mmol) and
aromatic aldehydes, namely, 3,4-dimethoxy-, 3,4,5-trimeth-
oxy-, p-chloro- or p-ﬂuoro-, p-N,N-dimethylaminobenzalde-
hyde (20 mmol) in MeOH (50 mL) in the presence of sodium
methoxide (10 mmol) was left for 14 days at room tempera-
ture. The obtained solid was ﬁltered off, dried and crystallized
from the proper solvent to give the corresponding arylmethyl-
ene derivatives 2a–e, respectively.
5.1.2. Method B
To a mixture of 3-methylcyclohexanone 1 (1.12 g, 10 mmol),
the appropriate aromatic aldehydes, namely, 3,4-dimethoxy-,
3,4,5-trimethoxy-, p-chloro-, p-ﬂuoro- or p-N,N-dimethyl
aminobenzaldehyde (20 mmol) in ethanol (50 mL), potassium
hydroxide (10 mmol) in 5 mL H2O was added. The reaction
Table 1 Antimicrobial activity of the newly synthesized compounds.
Comp. No. Inhibition zones (cm)
Gram-positive bacteria Gram-negative bacteria Yeast Fungi
Bacillus subtilis Bacillus aureus Staphylococcus aureus Escherichia coli Candida albicans Aspergillus niger
2a 1.05 1.35 1.20 – – 1.75
b 1.00 1.55 1.85 0.65 – 0.90
c 0.95 1.25 – 0.45 0.65 2.10
d 0.75 – 0.95 0.70 – –
e 1.15 1.95 1.85 0.55 – 0.85
3a 1.55 2.05 1.10 0.60 0.70 –
b 1.95 – – 0.70 – 1.50
4a 1.40 1.85 1.00 – – 1.95
b 1.75 1.15 1.90 0.50 – 1.60
5a 0.95 1.05 – – – 2.05
b 0.90 2.00 1.05 0.50 – 1.55
c 1.90 1.55 0.90 – – –
d 1.05 1.65 1.95 0.45 – 2.00
6a 1.85 1.70 0.95 0.55 –
b 0.95 – 0.90 0.75 – 1.65
c 0.90 2.00 0.85 0.60 – 2.10
d 1.10 1.75 1.85 – – 1.45
7a 1.85 1.60 1.05 – 0.80 –
b 0.90 2.05 1.00 0.65 – 2.05
c 0.80 1.75 1.90 0.55 0.70 –
d 1.90 1.60 1.15 – – 1.70
Ampicillin 1.15 2.50 1.30 0.75 – 2.30
Chloramphinicol 2.00 2.10 2.00 0.95 – 2.10
512 U.W. Hawas et al.mixture was stirred at room temperature for 2 h, the solid
formed was collected by ﬁltration and crystallized from the
proper solvent to give the corresponding arylmethylene deriv-
atives 2a–e, respectively.
5.1.3. 2,6-Bis-(3,4-dimethoxybenzylidene)-3-
methylcyclohexanone (2b)
Yield 95% [A], 82% [B]; mp 157–159 C (EtOH); IR (KBr,
cm–1): 1680, 1660; 1H NMR: 7.72 and 7.65 (2s, 2H, benzylic
proton), 7.54 and 7.33 (2s, 4H, ArH), 3.83, 3.75, 3.61 (3s,
18H, 6OCH3), 3.28 (m, 1H, CH), 1.92–1.54 (m, 4H, cyclohexene
protons), 1.24 (d, J= 6.8 Hz, 3H, CH3); MS (EI): m/z 468
[M+] (100), 453 [M+-CH3] (65), 285 [453-Ph(OCH3)3, H]
(54); Anal. Calcd for C27H32O7: C, 69.21; H, 6.88. Found: C,
69.18; H, 6.84.
5.1.4. 2,6-Bis-(p-ﬂuorobenzylidene)-3-methylcyclohexanone
(2d)
Yield 85% [A], 78% [B]; mp 103–105 C (EtOH); IR (KBr,
cm–1): 1658, 1598; 1H NMR: 7.70 and 7.68 (2s, 2H, benzylic
protons), 7.54–7.33 (m, 8H, ArH), 3.51 (m, 1H, CH), 2.92–
1.85 (m, 4H, cyclohexene protons), 1.26 (d, J= 6.8 Hz, 3H,
CH3); MS (EI): m/z 324 [M
+] (100), 296 [M+-C‚O] (38),
281 [296-CH3] (37); Anal. Calcd for C21H18F2O: C, 77.76; H,
5.59. Found: C, 77.73; H, 5.57.
5.1.5. 2,6-Bis-(p-N-dimethylbenzylidene)-3-
methylcyclohexanone (2e)
Yield 80% [A], 65% [B]; mp 123–125 C (EtOH); IR (KBr,
cm–1): 1681, 1663; 1H NMR: 7.54 and 7.32 (2s, 2H, benzylic
protons), 7.28–6.87 (m, 8H, ArH), 2.94, 2.81 (2s, 12H, 4-
NCH3), 3.45 (m, 1H, CH), 2.86–1.64 (m, 4H, cyclohexene pro-
tons), 1.18 (d, J = 6.80 Hz, 3H, CH3); MS (EI): m/z 374 [M
+](100), 359 [M+-CH3] (65), 239 [359-Ph-N-CH3)2]; Anal. Calcd
for C25H30N2O: C, 80.17; H, 8.07; N, 7.48. Found: C, 80.07;
H, 8.00; N, 7.42.
5.2. Synthesis of 3a,b and 4a,b
To a solution of compounds 2a,b (5 mmol) in acetic acid
(50 mL), hydrazine hydrate or phenylhydrazine (5 mmol) was
added. The reaction mixture was reﬂuxed for 3 h, after cooling;
the mixture was poured onto cold water. The obtained solid
was collected by ﬁltration, dried and crystallized from the
proper solvent to give the corresponding indazole derivatives
3a,b and 4a,b, respectively.
5.2.1. 2-Acetyl-7-(34-dimethoxybenzylidene)-3-(3,4-
dimethoxyphenyl)-4-methyl-3,3a,4,5,6,7-hexahydro-2H-
indazole (3a)
Yield 55%; mp: 161–163 C (EtOH); IR (KBr, cm–1): 1627,
1673; 1H NMR: 7.53–6.68 (m, 7H, ArH + CH-benzylic),
4.58 (d, J = 7.20 Hz, 1H, CH), 3.92, 3.88 (2s, 12H, 4OCH3),
3.32 (m, 1H, CH), 2.74 (m, 2H, CH2), 2.51 (s, 3H, COCH3),
1.89 (m, 1H, CH), 1.65 (m, 2H, CH2), 1.42 (d, J = 6.76 Hz,
3H, CH3); MS (EI): m/z 464 [M
+] (100), 284 [M+-dimethoxy-
benzyl-idene] (45); Anal. Calcd for C27H32N2O5: C, 69.81; H,
6.94; N, 6.03. Found: C, 69.76; H, 6.90; N, 5.95.
5.2.2. 2-Acetyl-7-(3,4,5-trimethoxybenzylidene)-3-(3,4,5-
trimethoxyphenyl)-4-methyl-3,3a,4,5,6,7-hexahydro-2H-
indazole (3b)
Yield 52%; mp 208–210 C (Dioxane); IR (KBr, cm–1): 1625,
1670; 1H NMR: 7.12–6.65 (m, 5H, ArH+ benzylic proton),
4.68 (d, J = 7.18 Hz, 1H, CH), 3.82, 3.73, 3.65 (3s, 18H,
6OCH3), 3.45 (m, 1H, CH), 2.82 (m, 2H, CH2), 2.43 (s, 3H,
Synthesis of some thiopyrimidine and thiazolopyrimidines 513COCH3), 2.12 (m, 1H, CH), 1.87 (m, 2H, CH2), 1.34 (d,
J = 6.75 Hz, 3H, CH3); MS (EI): m/z 524 [M
+] (57), 481
[M+-COCH3] (100), 313 [481-trimethoxy-benzilidine, H] (74),
287 [313-CN]; Anal. Calcd for C29H36N2O7: C, 66.39; H,
6.92; N, 5.34. Found: C, 66.32; H, 6.86; N, 5.28.
5.2.3. 7-(3,4-Dimethoxybenzylidene)-3-(3,4-dimethoxyphenyl)-
2-phenyl-4-methyl-3,3a,4,5,6,7-hexahydro-2H-indazole (4a)
Yield 65%; mp 127–129 C (MeOH); IR (KBr, cm–1): 1650;
1H NMR: 7.71–6.68 (m, 12H, ArH+ benzylic proton), 4.58
(d, J = 7.25 Hz, 1H, CH), 3.95, 3.93 (2s, 12H, 4OCH3), 3.32
(m, 1H, CH), 2.74 (m, 2H, CH2), 1.89 (m, 1H, CH), 1.65 (m,
2H, CH2), 1.42 (d, J = 6.75 Hz, 3H, CH3); MS (EI): m/z
498 [M+] (15), 408 [M+-PhNH] (100), 285 [408-4OCH3 -H]
(74), 257 [285- N,CH2] (54); Anal. Calcd for C31H34N2O4: C,
74.67; H, 6.87; N, 5.62. Found: C, 74.60; H, 6.81; N, 5.56.
5.2.4. 7-(3,4,5-Trimethoxybenzylidene)-3-(3,4,5-
trimethoxyphenyl)-2-phenyl-4-methyl-3,3a,4,5,6,7-hexa-hydro-
2H-indazole (4b)
Yield 60%; mp 133–135 C (EtOH); IR (KBr, cm–1): 1656; 1H
NMR: 7.34–6.62 (m, 10H, ArH + CH-benzylic), 4.58 (d,
J = 7.30 Hz, 1H, CH), 3.93, 3.88, 3.82 (3s, 18H, 6OCH3),
3.32 (m, 1H, CH), 2.80 (d, 2H, CH2), 1.94 (m, 1H, CH),
1.62 (m, 2H, CH2), 1.27 (d, J = 6.82 Hz, 3H, CH3); MS
(EI): m/z 558 [M+] (100), 377 [M+-trimethoxybenzylidene]
(25), 255 [377-PhNN, OCH3] (18); Anal. Calcd for
C33H38N2O6: C, 70.95; H, 6.86; N, 5.01. Found: C, 70.90; H,
6.80; N, 4.95.
5.3. Synthesis of 8-(substituted-benzylidene)-4-(substituted-
phenyl)-5-methyl-3,4,5,6,7,8-hexahydro-1H-quinazoline-2-
thione (5a–d)
A mixture of compound 2a–d (10 mmol) and thiourea (0.76 g,
10 mmol) in ethanolic potassium hydroxide (2 g in 100 mL eth-
anol) was reﬂuxed for 3 h. The reaction mixture was poured
onto cold water acidiﬁed with hydrochloric acid (1N); the ob-
tained precipitate was ﬁltered off, washed with water, dried
and crystallized from the proper solvent to give the corre-
sponding thioxopyrimidine derivatives 5a–d, respectively.
5.3.1. 8-(3,4-Dimethoxybenzylidene)-4-(3,4-dimethoxyphenyl)-
5-methyl-3,4,5,6,7,8-hexahydro-1H-quina-zoline-2-thione (5a)
Yield 85%; mp 204–206 C (EtOH); IR (KBr, cm–1): 3400–
3320, 1600, 1250; 1H NMR: 8.89, 9.15 (2s, 2H, 2NH exchange-
able with D2O), 7.19–7.03 (m, 7H, ArH+ benzylic proton),
5.42 (d, J = 7.32 Hz, 1H, CH), 3.85, 3.78 (2s, 12H, 4OCH3),
3.48 (m, 1H, CH), 2.98–1.80 (m, 4H, 2CH2), 1.31 (d,
J = 6.68 Hz, 3H, CH3); MS (EI): m/z 466 [M
+] (68.6), 382
[M+-C‚S, 2NH] (100), 205 [414-CH2-C‚CH-Ph(OCH3)2]
(54); Anal. Calcd for C26H30N2O4S: C, 66.92; H, 6.48; N,
6.00; S, 6.87. Found: C, 66.90; H, 6.46; N, 5.99; S, 6.85.
5.3.2. 8-(3,4,5-Timethoxybenzylidene)-4-(3,4,5-
trimethoxyphenyl)-5-methyl-3,4,5,6,7,8-hexahydro-1H-
quinazoline-2-thione (5b)
Yield 90%; mp 152–154 C (MeOH); IR (KBr, cm–1): 3368–
3312, 1610, 1248; 1H NMR: 9.30, 9.10 (2s, 2H, 2NH exchange-
able with D2O), 7.43 (s, 1H, benzylic proton), 6.94, 6.86 (2s,
4H, ArH), 5.21 (d, J = 7.29 Hz, 1H, CH), 3.44 (m, 1H,
CH), 2.4–1.80 (m, 4H, 2CH2), 1.23 (d, J = 6.68 Hz, 3H,CH3); MS (EI): m/z 526 [M
+] (68.6), 348 [M+-trimethoxyben-
zlidine] (100), 181 [348-trimethoxyphenyl, 3H] (62); Anal.
Calcd for C28H34N2O6S: C, 63.85; H, 6.50; N, 5.32; S, 6.08.
Found: C, 63.87; H, 6.47; N, 5.31; S, 6.05.
5.3.3. 8-(p-Chlorobenzylidene)-4-(p-chlorophenyl)-5-methyl-
3,4,5,6,7,8-hexahydro-1H-quinazoline-2-thione (5c)
Yield 85%; mp: 230–232 C (EtOH); IR (KBr, cm–1): 3350–
3255, 1605, 1252; 1H NMR: 9.50, 9.20 (2s, 2H, 2NH exchange-
able with D2O), 7.60–7.20 (m, 9H, ArH + CH-benzylic), 5.34
(d, J = 7.48 Hz, 1H, CH), 3.20 (m, 1H, CH), 2.40–1.80
(m, 4H, 2CH2), 1.18 (d, J = 6.72 Hz, 3H, CH3); MS (EI):
m/z 414 [M+] (68), 413 [M+-H] (100), 303 [414- p-Cl-Ph]
(54), 176 [303- p-Cl-Ph, CH3, H] (43); Anal. Calcd for
C22H20Cl2N2S: C, 63.61; H, 4.85; Cl, 17.07; N, 6.74; S, 7.72.
Found: C, 63.67; H, 4.82; Cl, 17.00; N, 6.72; S, 7.73.
5.3.4. 8-(p-Fluorobenzylidene)-4-(p-ﬂuorophenyl)-5-methyl-
3,4,5,6,7,8-hexahydro-1H-quinazoline-2-thione (5d)
Yield 87%; mp 173–175 C (MeOH); IR (KBr, cm–1): 3380–
3290, 1602, 1245; 1H NMR: 9.70, 9.40 (2s, 2H, 2NH exchange-
able with D2O), 7.74–7.36 (m, 9H, ArH + CH-benzylic), 5.28
(d, J = 7.25 Hz, 1H, CH), 3.29 (m, 1H, CH), 2.78–1.96 (m,
4H, 2CH2), 1.19 (d, J = 6.80 Hz, 3H, CH3); MS (EI): m/z
382 [M+] (100), 287 [M+-(p-F-Ph)] (65), 146 [287-(p-F-Ph),
SH] (54); Anal. Calcd for C22H20F2N2S: C, 69.08; H, 5.27;
N, 7.32; S, 8.38. Found: C, 69.05; H, 5.30; N, 7.31; S, 8.34.
5.4. Synthesis of 9-(substituted-benzylidene)-5-(substituted-
phenyl)-6-methyl-6,7,8,9-tetrahydro-5H-thiazolo[2,3-
b]quinazolin-3-one (6a–d)
A mixture of compound 5a–d (2 mmol), chloroacetic acid
(0.1 g, 2 mmol), sodium acetate anhydrous (25 g) glacial ace-
tic acid and acetic anhydride (40 mL, 3:1) was reﬂuxed for 3 h.
After cooling, the reaction mixture was poured gradually with
stirring onto cold water, the solid formed was ﬁltered off,
washed with water, dried and crystallized from proper solvent
to give the corresponding thiazolopyrimidine derivatives 6a–d,
respectively.
5.4.1. 9-(3,4-Dimethoxybenzylidene)-5-(3,4-dimethoxyphenyl)-
6-methyl-6,7,8,9-tetrahydro-5H-thiazolo [2,3-b]quinazolin-3-
one (6a)
Yield 70%; mp 104–106 C (EtOH); IR (KBr, cm–1): 1718,
1639; 1H NMR: 7.52 (s, 1H, benzylic proton), 7.48–7.32 (m,
6H, ArH), 5.54 (s, 1H, CH), 3.82 (s, 2H, CH2, thiazole), 2.89
(m, 2H, CH2), 2.46 (m, 1H, CH), 1.76 (m, 2H, CH2), 1.10
(d, J= 6.74 Hz, 3H, CH3); MS (EI): m/z 466 [M
+] (68), 382
[M+-C‚S, CHCH2CH3, 2H], 205 [382-3,4-dimethoxybenzlid-
ene, CH2]; Anal. Calcd for C28H30N2O5S: C, 66.38; H, 5.96; N,
5.53; S, 6.33. Found: C, 66.35; H, 5.99; N, 5.50; S, 6.31.
5.4.2. 9-(3,4,5-Trimethoxybenzylidene)-5-(3,4,5-
trimethoxyphenyl)-6-methyl-6,7,8,9-tetrahydro-5H-
thiazolo[2,3-b]quinazolin-3-one (6b)
Yellow solid, yield 65%; mp: 135–137 C (MeOH); IR
(KBr, cm–1): 1724, 1626; 1H NMR: 7.48 (s, 1H, benzylic pro-
ton), 7.41, 7.32 (2s, 4H, ArH), 5.49 (s, 1H, CH), 3.79 (s, 2H,
CH2, thiazole), 2.88 (m, 2H, CH2), 2.35 (m, 1H, CH), 1.69
(m, 2H, CH2), 1.00 (d, J = 6.68 Hz, 3H, CH3); MS (EI): m/z
566 [M+] (68), 565 [M+-H] (100), 506 (45), 369 (16), 233
514 U.W. Hawas et al.(75); Anal. Calcd for C30H34N2O7S: C 63.59, H 6.05, N 4.94, S
5.66, found: C 63.52, H 5.98, N 4.88, S 5.60.
5.4.3. 9-(p-Chlorobenzylidene)-5-(p-chlorophenyl)-6-methyl-
6,7,8,9-tetrahydro-5H-thiazolo[2,3-b]-quinazolin-3-one (6c)
Yellow solid, yield 80%; mp: 158–160 C (EtOH); IR (KBr,
cm–1): 1724, 1622; 1H NMR: 7.58 (s, 1H, benzylic proton),
7.76–7.23 (m, 8H, ArH), 5.53 (s, 1H, CH), 3.79 (s, 2H, CH2, thi-
azole), 2.68 (m, 2H, CH2), 2.35 (m, 1H, CH), 1.98 (m, 2H, CH2),
1.12 (d, J = 6.69 Hz, 3H, CH3); MS (EI): m/z 454 [M
+-1] (83),
343 [M+-(p-chlorophenyl)] (100), 217 [343-(p-chlorophenyl),
CH3] (54); Anal. Calcd for C24H20Cl2N2OS: C 63.29, H 4.42,
N 6.15, S 7.04, found: C 63.25, H 4.40, N 6.12, S 7.06.
5.4.4. 9-(p-Fluorobenzylidene)-5-(p-ﬂuorophenyl)-6-methyl-
6,7,8,9-tetrahydro-5H-thiazolo[2,3-b]-quina-zolin-3-one (6d)
Yellow solid, yield 75%; mp: 198–200 C (MeOH); IR (KBr,
cm–1): 1730, 1615; 1H NMR: 7.53 (s, 1H, benzylic proton),
7.42–6.95 (m, 8H, ArH), 5.50 (s, 1H, CH), 3.72 (s, 2H, CH2,
thiazole), 2.70 (m, 2H, CH2), 2.30 (m, 1H, CH), 1.50 (m, 2H,
CH2), 1.15 (d, J = 6.66 Hz, 3H, 6-CH3); MS (EI): m/z 422
[M+] (100), 327 [M+-(p-ﬂuorophenyl)], 299 [327-C‚O]; Anal.
Calcd for C24H20N2F2OS: C 68.22, H 4.77, N 6.63, S 7.59.
Found: C 68.20, H 4.79, N 6.60, S 7.55.
5.5. Synthesis of 2,9-bi(substituted-benzylidene)-5-(substituted-
phenyl)-6-methyl-6,7,8,9-tetrahydro-5H-thiazolo[2,3-
b]quinazolin-3-one (7a–d)
5.5.1. Method A
A mixture of compounds 5a–d (2 mmol), chloroacetic acid
(2 mmol), sodium acetate anhydrous (2 g) in glacial acetic acid
and acetic acid anhydride (40 mL, 3:1) was reﬂuxed for 12 min.,
then equimolecular amount of the appropriate aromatic alde-
hydes, namely, 3-bromo- or p-chloro- or 3,4,5-trimethoxy- or
3-bromobenzaldehyde (2 mmol) was added. The reaction mix-
ture was reﬂuxed for 2 h, allowed to cool, poured onto cold
water; the formed precipitate was ﬁltered off, dried and crystal-
lized from proper solvent to give the corresponding arylmethyl-
ene thiazolopyrimidine derivatives 7a–d, respectively.
5.5.2. Method B
A mixture of compounds 6a–d (2 mmol), equimolecular
amount of appropriate aromatic aldehydes, namely, 3-bromo-
or p-chloro- or 3,4,5-trimethoxy- or 3-bromobenzaldehydes
(2 mmol) in amixtur of acetic acid and acetic anhydride
(40 mL, 1:3 ratio) was reﬂuxed for 1.5 h. After cooling, the
reaction mixture was poured onto cold water; the formed solid
was collected by ﬁltration and crystallized from the proper sol-
vent to give the corresponding arylmethylene thiazolopyrimi-
dine derivatives 7a–d, respectively. The products were
identiﬁed by their m.p. and Rf-values in comparison with
authentic samples previously obtained by method A. The yield
from method A was better than from method B.
5.5.3. 9-(3,4-Dimethoxybenzylidene)-5-(3,4-dimethoxyphenyl)-
2-(3-bromobenzylidene)-6-methyl-6,7,8,9-tetrahydro-5H-
thiazolo[2,3-b]quinazolin-3-one (7a)
Yellow solid, yield 76% [A] and 68% [B]; mp: 188–190 C
(EtOH); IR (KBr): 1708 cm–1; 1HNMR: 7.75, 7.68 (2s, 2H, ben-
zylic protons), 7.40–6.61 (m, 10H, ArH), 5.63 (s, 1H, CH), 3.75,
3.73 (2s, 12H, 4OCH3), 2.70 (m, 2H, CH2), 2.30 (m, 1H, CH),1.50 (m, 2H, CH2), 1.16 (d, J = 6.82 Hz, 3H, CH3); MS (EI):
m/z 672 [M+] (58), 421 [M+- (dimethoxy-benzlidine, 2OCH3,
C=O, CH3)] (100), 165 [421-(3-bromobenzylidene, CH‚Ph)]
(21); Anal. Calcd for C35H33BrN2O5S: C 62.40, H 4.93, N
4.15, S 4.75, found: C 62.36, H 4.90, N 4.11, S 4.72.
5.5.4. 9-(3,4,5-Trimethoxybenzylidene)-5-(3,4,5-
trimethoxyphenyl)-2-(p-chlorobenzylidene)-6-methyl-6,7,8,9-
tetrahydro-5H-thiazolo[2,3-b]quinazolin-3-one (7b)
Orange crystals, yield 60% [A] and 55% [B]; mp: 210–212 C
(EtOH); IR (KBr): 1706 cm–1; 1H NMR: 7.84, 7.73 (2s, 2H,
benzylic protons), 7.44–6.92 (m, 8H, ArH), 5.53 (s, 1H, CH-),
3.82, 3.79, 3.72 (3s, 18H, 6OCH3), 2.70 (m, 2H, CH2), 2.30
(m, 1H, CH), 1.50 (m, 2H, CH2), 1.18 (d, J = 6.72 Hz, 3H,
CH3); MS (EI): m/z 688 [M
+] (24), 521 [M+-(p-chlorophenyl),
H] (24), 343 [521-(trimethoxybenzylidene), C‚O] (100), 269
[343-thiourea]; Anal. Calcd for C37H37ClN2O7S: C 64.47, H
5.41, N 4.06, S 4.65, found: C 64.40, H 5.35, N 4.00, S 4.59.
5.5.5. 9-(p-Chlorobenzylidene)-5-(p-chlorophenyl)-2-(3,4,5-
trimethoxybenzylidene)-6-methyl-6,7,8,9-tetrahydro-5H-
thiazolo[2,3-b]quinazolin-3-one (7c)
Yellow powder, yield 70% [A] and 65% [B]; mp: 147–149 C
(MeOH); IR (KBr): m= 1706 cm-1; 1H NMR: 7.72, 7.50 (2s,
2H, benzylic protons), 7.48–6.97 (m, 10H, ArH), 5.56 (s, 1H,
CH), 3.86 (s, 9H, 3OCH3), 2.70 (m, 2H, CH2), 2.30 (m, 1H,
CH), 1.50 (m, 2H, CH2), 1.20 (d, J = 6.77 Hz, 3H, CH3);
MS (EI): m/z 633 [M+] (46), 521 [M+-(p-chlorophenyl), H]
(100), 299 [521-(trimethoxybenzylidene), C‚O], 209 [299-thio-
urea, CH3, H]; Anal. Calcd for C34H30Cl2N2O4S: C 64.45, H
4.77, N 4.42, S 5.06, found: C 64.40, H 4.72, N 4.40, S 5.00.
5.5.6. 9-(p-Fluorobenzylidene)-5-(p-ﬂuorophenyl)-2-(3-
bromobenzylidene)-6-methyl-6,7,8,9-tetrahydro-5H-
thiazolo[2,3-b]quinazolin-3-one (7d)
Red solid, yield 72% [A] and 64% [B]; mp: 247–249 C
(EtOH); IR (KBr): m= 1704 cm–1; 1H NMR: 7.80, 7.60 (2s,
2H, benzylic protons), 7.70–7.60 (m, 12H, ArH), 5.8 (s, 1H,
CH), 3.60 (b, 1H, CH), 2.40–1.80 (m, 4H, 2CH2), 1.16 (d,
J = 6.67 Hz, 3H, CH3); MS (EI): m/z 589 [M
+] (73), 493
[M+-(p-ﬂuorophenyl), H] (100), 465 [493-C‚O], 251 [465-(3-
bromobenzylidene), C‚O, 2H]; Anal. Calcd for
C31H23BrF2N2OS: C 63.16, H 3.93, N 4.75, S 5.43, found: C
63.10, H 3.88, N 4.70, S 5.38.Acknowledgment
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